Other Events ·
Moleculin Biotech reports preclinical data showing Annamycin extends survival in pancreatic cancer models when combined with PD-1 blockade
MBRXMoleculin Biotech, Inc.
Moleculin Biotech announced new preclinical data demonstrating that its lead drug candidate, Annamycin (naxtarubicin), combined with PD-1 immune checkpoint blockade, significantly extended survival in syngeneic mouse models of advanced pancreatic ductal adenocarcinoma compared to either agent alone. The findings indicate that Annamycin achieves higher pancreatic tissue exposure than doxorubicin and increases infiltration of functional CD8+ T cells, potentially turning immunologically 'cold' tumors into 'hot' ones. These results support the evaluation of Annamycin in combination with approved PD-1 inhibitors for pancreatic cancer and other solid tumors. The data will be presented at the 6th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care. Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company advancing therapeutic candidates for hard-to-treat tumors and viruses, including Annamycin for acute myeloid leukemia.